Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.
OBJECTIVE
To assess the effect on various aspects of carbohydrate and lipid metabolism of administering a quick-release formulation of bromocriptine (Ergoset) to obese, nondiabetic, hyperinsulinemic women.


METHODS
Hourly concentrations of prolactin, glucose, insulin, free fatty acid (FFA), and triglyceride were measured for 24 h before and after approximately 8 weeks of treatment with Ergoset. In addition, fasting lipid and lipoprotein concentrations and the steady-state plasma glucose (SSPG) concentration in response to a continuous infusion of somatostatin, insulin, and glucose were determined before and after Ergoset administration.


RESULTS
Circulating prolactin concentrations were dramatically decreased (P < 0.001) following treatment, associated with a significant fall (P < 0.05) in 24-h-long plasma glucose, FFA, and triglyceride concentrations. Neither circulating plasma insulin concentrations nor the ability of insulin to mediate glucose disposal changed with treatment. Finally, fasting total cholesterol fell (P < 0.05) and the ratio of total to HDL cholesterol decreased (P = 0.06) in association with Ergoset treatment.


CONCLUSIONS
The fact that significant metabolic improvement was seen in the obese nondiabetic hyperinsulinemic women studied suggests that Ergoset could be of therapeutic benefit in clinical conditions of hyperglycemia and/or dyslipidemia.
Kamath
V
V
Department of Medicine, Stanford University, School of Medicine, CA 94305-5013, USA.
Jones
C N
CN
Yip
J C
JC
Varasteh
B B
BB
Cincotta
A H
AH
Reaven
G M
GM
Chen
Y D
YD
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis* / Q000187:drug effects / Q000378:metabolism; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005215:Fasting; D005230:Fatty Acids, Nonesterified / Q000097:blood / Q000378:metabolism; D005260:Female; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007328:Insulin / Q000097:blood* / Q000378:metabolism; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D019518:Postprandial Period; D011388:Prolactin / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
D001786:Blood Glucose; D018491:Dopamine Agonists; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; D001971:Bromocriptine; D011388:Prolactin; D002784:Cholesterol